Business
DiaMedica Therapeutics to Present Research at International Stroke Conference
MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments
About this update from Diamedica Therapeutics Inc.
[{"type":"text","content":" MINNEAPOLIS--(BUSINESS WIRE)--\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the American Heart Association 2022 International Stroke Conference being held in New Orleans, LA and Virtually from February 9 – 11, 2022. For information about the event, visit: https://professional.heart.org/en/meetings/international-stroke-conference.\n\nThe DiaMedica abstracts include:\n\nAbstract Title: “Stroke Recurrence And Mortality With Recombinant Tissue Kallikrein Protein In The Remedy1 Phase 2 Trial”\n\nAbstract Title: “Randomized, Double-blind, Placebo-controlled, Adaptive Design Study To Evaluate Dm199 For The Treatment Of Acute Ischemic Stroke (ReMEDy2 Trial)”\n\nThese abstracts will be presented in person at Poster Hall B2 (Poster Boards CTP16 & CTP17) on Thursday February 10, 2022, from 12:30 PM – 01:15 PM. DiaMedica will also be exhibiting at the conference located in the main hall at booth 111.\n\nFollowing the session, a reprint of the abstracts will be accessible from DiaMedica’s website at: https://www.diamedica.com/investors/events-presentations.\n\nAbout DiaMedica Therapeutics Inc.\n\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit our website at www.diamedica.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20220125005323/en/\n\nScott Kellen\nChief Financial Officer\nPhone: (763) 496-5118\[email protected]\n\nSource: DiaMedica Therapeutics Inc.","length":4300,"tagName":"div"}]